Although significant improvements have been made in the outcomes of children with cancer,
the pace of improvement has slowed in recent years as the limits of therapy intensification …

Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving
survival and reducing long-term side-effects for children and adolescents with cancer. The …

Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) classic
Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous …

Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL)
relapse. Although brentuximab vedotin has demonstrated excellent activity in ALCL, it has …

Despite improved outcomes achieved in the last decades for children with newly diagnosed
leukaemia and lymphoma, treatment of patients with refractory/relapsed disease remains a …

Summary The 6th International Symposium on Childhood, Adolescent and Young Adult
(CAYA) Non‐Hodgkin Lymphoma (NHL) was held in Rotterdam, Netherlands, 26–29 …

PURPOSE To analyze the efficacy of a risk-stratified treatment of children with relapsed
anaplastic large cell lymphoma (ALCL). The ALCL-Relapse trial (ClinicalTrials. gov …

Advances in the management of Hodgkin lymphoma in children, adolescents and young
adult have resulted in survival outcomes exceeding 90%. The risk of late toxicity, however …

Importance Retrieval strategies for children, adolescents, and young adults with relapsed
classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic …

The objective of this guideline is to aid clinicians in making individual salvage treatment
plans for pediatric and adolescent patients with first relapse or refractory (R/R) classical …